Novel drug mechanisms in development for heart failure-Reference-Cited by-同舟云学术

Novel drug mechanisms in development for heart failure

Published:2014-05-06 Issue:6 Volume:466 Page:1219-1225
ISSN:0031-6768
Container-title:Pflügers Archiv - European Journal of Physiology
language:en
Short-container-title:Pflugers Arch - Eur J Physiol

Author:

Khodjaev Soidjon D.,Teerlink John R.,Malik Fady I.

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Clinical Biochemistry,Physiology

Link

http://link.springer.com/content/pdf/10.1007/s00424-014-1528-9.pdf

Reference44 articles.

1. Abassi ZA, Powell JR, Golomb E, Keiser HR (1992) Renal and systemic effects of urodilatin in rats with high-output heart failure. Am J Physiol 262:F615–F621

2. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden J, Gielen-Haertwig H, Schlemmer K, Mittendorf J, Paulsen H, Platzek J, Kolkhof P (2012) Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7:1385–1403. doi: 10.1002/cmdc.201200081

3. Bauersachs J (2013) The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J 34:2426–2428. doi: 10.1093/eurheartj/eht235

4. Baylis C (1999) Relaxin may be the “elusive” renal vasodilatory agent of normal pregnancy. Am J Kidney Dis 34:1142–1144. doi: 10.1016/S0272-6386(99)70024-7 , discussion 1144–5

5. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC (2011) Cardiorenal actions of TRV120027, a novel ß-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4:770–778. doi: 10.1161/CIRCHEARTFAILURE.111.962571

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatments for Heart Failure;Comprehensive Medicinal Chemistry III;2017